Jane S. Ricciuti, RPh, MS


October 21, 2003

In This Article

Antidiabetic Agents

(repaglinide) Tablets

Manufacturer: Novo Nordisk

Drug Approval Classification: Supplemental New Drug Application (Approval Date: 09/01/03)

Precautions/Drug Interaction: Results of a pharmacokinetic drug-drug interaction study of Prandin (repaglinide) and Lopid (gemfibrozil) found that concomitant use may result in enhanced and prolonged glucose-lowering effects of repaglinide. Adding itraconazole to repaglinide and gemfibrozil therapy resulted in even higher repaglinide levels.

Prandin (repaglinide) Tablets Labeling

Prandin(repaglinide) Tablets